Pharmacotherapy with alpha-1 adrenergic blockers and lipid spectrum correction in patients with urinary disorders

The study was based on treatment outcomes in a group of 130 patients aged 18–81 years. Subgroups were formed according to gender and age criteria, which included 56 men and 74 women, and were also divided into subgroups under 65 years of age and after 65. Treatment lasting continuously from 11 to 18 months was carried out in the form of combination therapy with the prescription of α1‑blockers (terazosin, doxazosin) in combination with vitamin-like drugs (levocarnitine, alpha-lipoic acid) in dosages according to the official instructions for the drug. The work involved systems for tabular assessment of the clinical symptoms of urinary disorders, as well as instrumental, laboratory, and statistical methods (Mann — Whitney test, Spearman's rank correlation coefficient).
Results. Against the background of the prescribed treatment, HDL levels significantly changed from 1.3 to 1.38 mmol/L, as well as VLDL from 0.88 to 0.72 mmol/L in the general observation group. In some indicators, particularly total cholesterol, low-density lipoprotein, and triglycerides, no dynamics were noted. In the men subgroup, the indicators of both HDL and VLDL changed significantly and reliably from 1.2 to 1.29 mmol/L and, accordingly, from 0.79 to 0.65 mmol/L. In the 65-yearold subgroup, VLDL levels significantly decreased from 0.88 to 0.76 mmol/L and triglyceride levels from 1.9 to 1.65 mmol/L, respectively. In the subgroup of patients aged >65 years, there was a significant increase in HDL from 1.29 to 1.46 mmol/L.
Conclusion. Long-term combination therapy over 11 months, including alpha1 inhibitors in combination with vitamin-like drugs, significantly changed the lipid spectrum. The best outcomes of pharmacotherapy were observed in the male subgroup and in patients aged >65 years.

1. Zaitseva ED, Menshakov YaN. The effect of metabolic syndrome on the development of various types of cancer. Aktual'nye voprosy onkodermatologii. 2022;11-13. (In Russ.).

2. Ershova AI, Al Rashi DO, Ivanova AA, et al. Secondary hyperlipidemias: etiology and pathogenesis. Russian Journal of Cardiology. 2019;24(5):74-81. (In Russ.). doi: 10.15829/1560-4071-2019-5-74-81.

3. Sumarokov AB, Chubykina UV, Ezhov MV. Rhabdomyolysis is a rare complication of statin therapy. Case report and literature review. Russian Cardiology Bulletin. 2022;17(1):84‑92. (In Russ.). doi: 10.17116/Cardiobulletin20221701184.

4. Neurology: in 3 volumes / V.V. Danilov, V.V. Danilov. — Vladivostok: Club of Directors. 2019. Vol. 1. (In Russ.). ISBN 978-5-600-02524-0

5. Torvik D, Madsbu HP. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Br J Clin Pharmacol. 1986;21 Suppl 1(Suppl 1): 69S-75S. doi: 10.1111/j.1365-2125.1986.tb02856.x.

6. Kirk JK, Konen JC, Shihabi Z, Rocco MV, Summerson JH. Effects of Terazosin on Glycemic Control, Cholesterol, and Microalbuminuria in Patients with Non--Insulin-Dependent Diabetes Mellitus and Hypertension. Am J Ther. 1996 Sep;3(9):616-621. doi: 10.1097/00045391-199609000-00003.

7. Cubeddu LX, Pool JL, Bloomfield R, et al. Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension. Am J Hypertens. 1988 Apr;1(2):158-67. doi: 10.1093/ajh/1.2.158.

8. Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988 Jun;148(6):1280-8. doi: 10.1001/archinte.1988.00380060044012.

9. Lehtonen A, Himanen P, Saraste M, et al. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins. Br J Clin Pharmacol. 1986;21 Suppl 1(Suppl 1):77S-81S. doi: 10.1111/j.1365-2125.1986.tb02857.x.

10. Danilov VV, Volnikh IU, Bahareva OM, Muhotina AG. Urination disorders of women of different age groups. Pacific Medical journal. 2003;(1): 76-77. (In Russ.).